Gene: FOXL2

668
BPES|BPES1|PFRK|PINTO|POF3
forkhead box L2
protein-coding
3q22.3
Ensembl:ENSG00000183770 MIM:605597 Vega:OTTHUMG00000159889 UniprotKB:P58012
NG_012454.1
PubMed
0   ANCO-SNPs
ND|AD
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.521e-1 (AD)  2.958e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TBX30.726
FOXF10.701
LEF10.699
ESAM0.681
PEAR10.67
MMRN20.668
MECOM0.668
DLL40.666
FLT40.662
MYCT10.656

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
STAR-0.396
SVOP-0.392
ST6GALNAC5-0.387
FSTL5-0.385
CDH8-0.384
DACH2-0.382
GDA-0.379
KNCN-0.378
PAK3-0.376
ADAMTS3-0.374

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of FOXL2 mRNA17562736
C015001arsenitearsenite results in increased methylation of FOXL2 promoter23974009
D004958EstradiolEstradiol results in increased expression of FOXL2 mRNA21889601
C006780bisphenol Abisphenol A results in increased expression of FOXL2 mRNA21850400
C006780bisphenol Abisphenol A results in increased expression of FOXL2 mRNA22732146
C006780bisphenol Abisphenol A affects the expression of FOXL2 mRNA21786754
D002104CadmiumCadmium results in increased expression of FOXL2 mRNA24376830
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of FOXL2 mRNA24317228
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in decreased expression of FOXL2 mRNA24804967
D004051Diethylhexyl PhthalateDiethylhexyl Phthalate results in increased expression of FOXL2 mRNA27495896
D004726Endosulfan[Endosulfan co-treated with Flutamide] results in increased expression of FOXL2 mRNA22227439
D004726EndosulfanEndosulfan results in increased expression of FOXL2 mRNA22227439
C118739entinostatentinostat results in increased expression of FOXL2 mRNA27188386
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of FOXL2 mRNA21850400
D005485Flutamide[Endosulfan co-treated with Flutamide] results in increased expression of FOXL2 mRNA22227439
D005485FlutamideFlutamide results in increased expression of FOXL2 mRNA22227439
D007052IbuprofenIbuprofen results in decreased expression of FOXL2 mRNA28201806
C042720mercuric bromidemercuric bromide results in increased expression of FOXL2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
D008777MethyltestosteroneMethyltestosterone results in increased expression of FOXL2 mRNA29191790
D008777MethyltestosteroneMethyltestosterone results in decreased expression of FOXL2 mRNA21889601
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of FOXL2 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXL2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of FOXL2 mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of FOXL2 mRNA20813756
D010936Plant ExtractsPlant Extracts results in decreased expression of FOXL2 mRNA23557933
D012715Sesame OilSesame Oil results in decreased expression of FOXL2 mRNA29191790
D013629TamoxifenFOXL2 protein inhibits the reaction [[Tamoxifen results in increased activity of ESR1 protein] which results in increased expression of PTGS2 mRNA]19797124
D013629TamoxifenTamoxifen promotes the reaction [ESR1 protein binds to FOXL2 protein]19797124
D013629TamoxifenTamoxifen results in decreased expression of FOXL2 mRNA24769059
D013629TamoxifenTamoxifen results in decreased expression of FOXL2 protein24769059
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FOXL2 mRNA24058054
D014212TretinoinTretinoin results in increased expression of FOXL2 mRNA21934132
D014635Valproic AcidValproic Acid affects the expression of FOXL2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of FOXL2 mRNA23179753|2718838
D014635Valproic AcidValproic Acid results in increased methylation of FOXL2 gene29154799
D014635Valproic AcidValproic Acid affects the expression of FOXL2 mRNA17963808
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of FOXL2 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0003677DNA binding-IDA16720712  
GO:0003677DNA binding-TAS11175783  
GO:0003700DNA-binding transcription factor activity-ISS-  
GO:0003700DNA-binding transcription factor activity-NAS11175783  12471206  
GO:0005515protein binding-IPI16153597  
GO:0030331estrogen receptor binding-IEA-  
GO:0031624ubiquitin conjugating enzyme binding-IPI19744555  
GO:0043028cysteine-type endopeptidase regulator activity involved in apoptotic process-IMP16153597  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0001541ovarian follicle development-IMP12161610  
GO:0001541ovarian follicle development-ISS-  
GO:0001555oocyte growth-IEA-  
GO:0002074extraocular skeletal muscle development-IMP12630957  
GO:0006309apoptotic DNA fragmentation-IMP16153597  
GO:0006357regulation of transcription by RNA polymerase II-IBA21873635  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0007338single fertilization-IEA-  
GO:0009653anatomical structure morphogenesis-IBA21873635  
GO:0019101female somatic sex determination-IEA-  
GO:0030154cell differentiation-IBA21873635  
GO:0030154cell differentiation-NAS12471206  
GO:0033686positive regulation of luteinizing hormone secretion-IEA-  
GO:0043065positive regulation of apoptotic process-IGI16153597  
GO:0043065positive regulation of apoptotic process-IMP16153597  
GO:0043280positive regulation of cysteine-type endopeptidase activity involved in apoptotic process-IMP16153597  
GO:0045892negative regulation of transcription, DNA-templated-IDA19744555  
GO:0045893positive regulation of transcription, DNA-templated-ISS-  
GO:0045944positive regulation of transcription by RNA polymerase II-IEA-  
GO:0046881positive regulation of follicle-stimulating hormone secretion-IEA-  
GO:0048048embryonic eye morphogenesis-IEA-  
GO:0060014granulosa cell differentiation-IEA-  
GO:0060065uterus development-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA12471206  
GO:0005654nucleoplasm-TAS-  
GO:0045171intercellular bridge-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-2990846SUMOylationTAS
R-HSA-3108232SUMO E3 ligases SUMOylate target proteinsTAS
R-HSA-3232118SUMOylation of transcription factorsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23599765Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer. (2013 Apr)Zhao YOncol Lett
29162857Temporal expression pattern of genes during the period of sex differentiation in human embryonic gonads. (2017 Nov 21)Mamsen LSSci Rep
24746205The expression of FOXL2 in pancreatic, hepatobiliary, and renal tumors with ovarian-type stroma. (2014 May)Westerhoff MHum Pathol